A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)

Xian Shi(Tongji Hospital), Minghui Sun(Nanjing University of Information Science and Technology), Qi Cheng(Tongji Hospital), Yuyang Zhao(Tongji Hospital), Shurong Zou(Tongji Hospital)
Osteoporosis International
August 18, 2023
Cited by 9


Related Papers